Literature DB >> 11520890

Partial resistance to malonate-induced striatal cell death in transgenic mouse models of Huntington's disease is dependent on age and CAG repeat length.

O Hansson1, R F Castilho, L Korhonen, D Lindholm, G P Bates, P Brundin.   

Abstract

Transgenic Huntington's disease (HD) mice, expressing exon 1 of the HD gene with an expanded CAG repeat, are totally resistant to striatal lesion induced by excessive NMDA receptor activation. We now show that striatal lesions induced by the mitochondrial toxin malonate are reduced by 70-80% in transgenic HD mice compared with wild-type littermate controls. This occurred in 6- and 12-week-old HD mice with 150 CAG repeats (line R6/2) and in 18-week-old, but not 6-week-old, HD mice with 115 CAG repeats (line R6/1). Therefore, we show for the first time that the resistance to neurotoxin in transgenic HD mice is dependent on both the CAG repeat length and the age of the mice. Importantly, most HD patients develop symptoms in adulthood and exhibit an inverse relationship between CAG repeat length and age of onset. Transgenic mice expressing a normal CAG repeat (18 CAG) were not resistant to malonate. Although endogenous glutamate release has been implicated in malonate-induced cell death, glutamate release from striatal synaptosomes was not decreased in HD mice. Malonate-induced striatal cell death was reduced by 50-60% in wild-type mice when they were treated with either the NMDA receptor antagonist MK-801 or the caspase inhibitor zVAD-fmk. These two compounds did not reduce lesion size in transgenic R6/1 mice. This might suggest that NMDA receptor- and caspase-mediated cell death pathways are inhibited and that the limited malonate-induced cell death still occurring in HD mice is independent of these pathways. There were no changes in striatal levels of the two anti cell death proteins Bcl-X(L) and X-linked inhibitor of apoptosis protein (XIAP), before or after the lesion in transgenic HD mice. We propose that mutant huntingtin causes a sublethal grade of metabolic stress which is CAG repeat length-dependent and results in up-regulation over time of cellular defense mechanisms against impaired energy metabolism and excitotoxicity.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11520890     DOI: 10.1046/j.1471-4159.2001.00482.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  13 in total

Review 1.  Mitochondrial nuclear receptors and transcription factors: who's minding the cell?

Authors:  Junghee Lee; Swati Sharma; Jinho Kim; Robert J Ferrante; Hoon Ryu
Journal:  J Neurosci Res       Date:  2008-04       Impact factor: 4.164

Review 2.  Killer proteases and little strokes--how the things that do not kill you make you stronger.

Authors:  Anne E O'Duffy; Yvette M Bordelon; BethAnn McLaughlin
Journal:  J Cereb Blood Flow Metab       Date:  2006-08-09       Impact factor: 6.200

Review 3.  The use of the R6 transgenic mouse models of Huntington's disease in attempts to develop novel therapeutic strategies.

Authors:  Jia Yi Li; Natalija Popovic; Patrik Brundin
Journal:  NeuroRx       Date:  2005-07

Review 4.  Mitochondrial calcium function and dysfunction in the central nervous system.

Authors:  David G Nicholls
Journal:  Biochim Biophys Acta       Date:  2009-03-17

Review 5.  Mouse models of Huntington's disease and methodological considerations for therapeutic trials.

Authors:  Robert J Ferrante
Journal:  Biochim Biophys Acta       Date:  2009-04-10

Review 6.  The energetics of Huntington's disease.

Authors:  Susan E Browne; M Flint Beal
Journal:  Neurochem Res       Date:  2004-03       Impact factor: 3.996

Review 7.  Towards an Understanding of Energy Impairment in Huntington's Disease Brain.

Authors:  Janet M Dubinsky
Journal:  J Huntingtons Dis       Date:  2017

8.  Pathological cell-cell interactions are necessary for striatal pathogenesis in a conditional mouse model of Huntington's disease.

Authors:  Xiaofeng Gu; Véronique M André; Carlos Cepeda; Shi-Hua Li; Xiao-Jiang Li; Michael S Levine; X William Yang
Journal:  Mol Neurodegener       Date:  2007-04-30       Impact factor: 14.195

Review 9.  Defining the role of the Bcl-2 family proteins in Huntington's disease.

Authors:  J Sassone; A Maraschi; F Sassone; V Silani; A Ciammola
Journal:  Cell Death Dis       Date:  2013-08-15       Impact factor: 8.469

Review 10.  Chronic Glutamate Toxicity in Neurodegenerative Diseases-What is the Evidence?

Authors:  Jan Lewerenz; Pamela Maher
Journal:  Front Neurosci       Date:  2015-12-16       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.